2. Search Result
Search Result
Results for "

XBP-1

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Natural
Products

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103248
    Toyocamycin
    5 Publications Verification

    Vengicide

    		 IRE1 Fungal Antibiotic Apoptosis CDK Infection Cancer
    Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM [1] .
    Toyocamycin
  • HY-18509
    IRE1α kinase-IN-2

    		IRE1 Cancer
    IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC50 of 0.82 μM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC50=3.12 μM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines [1].
    IRE1α kinase-IN-2
  • HY-139212
    IXA6

    		IRE1 Others
    IXA6 is a novel IRE1/XBP1s activator, and can induce IRE1 RNase activity [1].
    IXA6
  • HY-139214
    IXA4
    2 Publications Verification

    		 IRE1 Neurological Disease
    IXA4 is a highly selective, non-toxic IRE1/XBP1s activator. IXA4 activates IRE1/XBP1s signaling without globally activating the unfolded protein response (UPR) or other stress-responsive signaling pathways (e.g., the heat shock response or oxidative stress response). IXA4 reduces secretion of APP through IRE1 activation [1].
    IXA4
  • HY-U00460
    3,6-DMAD hydrochloride

    		IRE1 Cancer
    3,6-DMAD hydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD hydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD hydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD hydrochloride can be used for research of cancer [1] .
    3,6-DMAD hydrochloride
  • HY-RS15865
    XBP1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    XBP1 Human Pre-designed siRNA Set A contains three designed siRNAs for XBP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    XBP1 Human Pre-designed siRNA Set A
    XBP1 Human Pre-designed siRNA Set A
  • HY-158393
    IRE1a-IN-2

    		IRE1 Cancer
    IRE1a-IN-2 (Compound 30) is an IRE1α inhibitor, with an IC50 of over than 200 nM for XBP1 mRNA. IRE1a-IN-2 can be used for the research of cancer [1].
    IRE1a-IN-2
  • HY-158386
    IRE1a-IN-1

    		IRE1 Cancer
    IRE1a-IN-1 (Compound 10) is an IRE1α inhibitor, with an IC50 of less than 100 nM for XBP1 mRNA. IRE1a-IN-1 can be used for the research of cancer [1].
    IRE1a-IN-1
  • HY-145425
    PAIR2

    		IRE1 Cancer
    PAIR2 is a potent and selective partial antagonist of IRE1α RNase. PAIR2 can completely occupy IRE1α’s ATP-binding site in cells and block the ability of a potent KIRA to inhibit XBP1 splicing [1].
    PAIR2
  • HY-U00460B
    3,6-DMAD dihydrochloride

    		IRE1 Cancer
    3,6-DMAD dihydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD dihydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD dihydrochloride can be used for research of cancer [1] .
    3,6-DMAD dihydrochloride
  • HY-161672
    G-5758

    		Liposome IRE1 Cancer
    G-5758 is an orally available IRE1α inhibitor with an IC50 of 38 nM for XBP1s. G-5758 is well tolerated in multiple myeloma models (KMS-11) at oral doses up to 500 mg/kg in rats. G-5758 exhibits pharmacodynamics comparable to that of induced IRE1 knockdown [1].
    G-5758
  • HY-124293
    AA147
    3 Publications Verification

    		 ATF6 Reactive Oxygen Species Neurological Disease Metabolic Disease
    AA147 is a endoplasmic reticulum (ER) proteostasis regulator. AA147 promotes protection against oxidative damage in neuronal cells and prevents endothelial barrier dysfunction by activating ATF6 arm (selectively) of the unfolded protein response (UPR) and the NRF2 oxidative stress response. AA147 can rebalances XBP1s expression in vivo, and also induces survival motor neuron (SMN) expression and spinal motorneuron (MN) protection [1] .
    AA147
  • HY-A0098
    Tunicamycin
    Maximum Cited Publications
    95 Publications Verification

    		 Bacterial Fungal Influenza Virus Antibiotic Infection Inflammation/Immunology Cancer
    Tunicamycin is a mixture of homologous nucleoside antibiotic that inhibits N-linked glycosylation and blocks GlcNAc phosphotransferase (GPT). Tunicamycin causes accumulation of unfolded proteins in cell endoplasmic reticulum (ER) and induces ER stress, and causes blocking of DNA synthesis and cell cycle arrest in G1 phase. Tunicamycin inhibits gram-positive bacteria, yeasts, fungi, and viruses and has anti-cancer activity [1] .Tunicamycin increases exosome release in cervical cancer cells .
    Tunicamycin
  • HY-104040
    MKC8866
    5+ Cited Publications

    Orin1001

    		 IRE1 Cancer
    MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM [1]. MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
    MKC8866

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: